Norges Bank
RNA

Norges Bank’s Atrium Therapeutics RNA Stock Holding History

Norges Bank’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.7M Buy
+126,575
New +$1.65M ﹤0.01% 1514

Other funds holding RNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CL
CRCM LP San Francisco, California $144M AUM 26.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $190M AUM 51.6% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.8% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
CIEC
Crédit Industriel et Commercial Paris France, France $1.55B AUM 42.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Norges Bank's RNA Position: Q2 2026 in Review

Norges Bank opened a new position in Atrium Therapeutics (RNA) in Q2 2026: 126,575 shares worth $1.7M. The stake represents ﹤0.01% of the portfolio and ranks #1514 among its holdings.

75 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • Norges Bank held 126,575 shares of Atrium Therapeutics worth $1.7M as of Q2 2026.
  • Atrium Therapeutics was a new Norges Bank position in Q2 2026.
  • Atrium Therapeutics made up ﹤0.01% of Norges Bank's portfolio in Q2 2026, its #1514 holding.
  • 75 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Norges Bank's 13F filing for Q2 2026, filed 12 Aug 2026.